Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Pharmacological treatments for agitation and aggression in patients with Alzheimer's disease have shown limited efficacy. The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed. METHOD: In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disease and clinically significant agitation, participants were randomly assigned to receive citalopram or placebo for 9 weeks, with the dosage titrated to 30 mg/day over the first 3 weeks. Five planned potential predictors of treatment outcome were assessed, along with six additional predictors. The authors then used a two-stage multivariate method to select the most likely predictors; grouped participants into 10 subgroups by their index scores; and estimated the citalopram treatment effect for each. RESULTS: Five covariates were likely predictors, and treatment effect was heterogeneous across the subgroups. Patients for whom citalopram was more effective were more likely to be outpatients, have the least cognitive impairment, have moderate agitation, and be within the middle age range (76-82 years). Patients for whom placebo was more effective were more likely to be in long-term care, have more severe cognitive impairment, have more severe agitation, and be treated with lorazepam. CONCLUSIONS: Considering several covariates together allowed the identification of responders. Those with moderate agitation and with lower levels of cognitive impairment were more likely to benefit from citalopram, and those with more severe agitation and greater cognitive impairment were at greater risk for adverse responses. Considering the dosages used and the association of citalopram with cardiac QT prolongation, use of this agent to treat agitation may be limited to a subgroup of people with dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Self-citationAntidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833 · cited 1×
“Given these results, alongwith the established associations of citalopram with delayed cardiac repolarization (18, 20) and with cognitive impairment (7), and given safety concerns of antidepressants for depressed elderly patients (21) and the FDA’s recommendation to avoid citalopram dosages over 20 mg/day in patients…”
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Self-citationNeuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378 · cited 1×
“Agitation isgenerallymultidetermined, may wax and wane, is often associated with psychosocial stress, disruption, intercurrent medical conditions, and drug effects, andoftencanbemanagedbyaddressing theunderlying conditions, without psychotropic medications (1, 2).”
Self-citationPollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Self-citationPollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257
Self-citationSertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250
Self-citationAalten, P., de Vugt, M. E., Jaspers, N., Jolles, J., & Verhey, F. R. J. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1316 · Cited by 247 · cited 1×
“Agitation isgenerallymultidetermined, may wax and wane, is often associated with psychosocial stress, disruption, intercurrent medical conditions, and drug effects, andoftencanbemanagedbyaddressing theunderlying conditions, without psychotropic medications (1, 2).”
Drye, L. T., Spragg, D., Devanand, D. P., Frangakis, C., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., Pelton, G., Pollock, B. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098426 · Cited by 59 · cited 2×
“Given these results, alongwith the established associations of citalopram with delayed cardiac repolarization (18, 20) and with cognitive impairment (7), and given safety concerns of antidepressants for depressed elderly patients (21) and the FDA’s recommendation to avoid citalopram dosages over 20 mg/day in patients…”
Self-citationCitalopram for agitation in Alzheimer's disease: Design and methods
Drye, L. T., Ismail, Z., Porsteinsson, A. P., Rosenberg, P. B., Weintraub, D., Marano, C., Pelton, G., Frangakis, C., Rabins, P. V., Munro, C. A., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.007 · Cited by 52
Self-citation
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationTeixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
“70,71 As discussed in the previous section, atypical antipsychotics should be reserved for more severe cases.”
BackgroundA 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
“Broadly, it has been speculated that patients with more severe agitation and cognitive impairments may be at a higher risk for developing AEs, while those with moderate agitation and cognitive impairments are more likely to experience therapeutic effects [69].”
BackgroundSelf-citationOxtoby, N. P., Shand, C., Cash, D. M., Alexander, D. C., & Barkhof, F. (2022) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2022.660581 · Cited by 14
“Closest to this work is the aforementioned study of the ADCS-MCI trial data by Edmonds, et al. (26), and the work of Schneider, et al. (32), but the approaches used in these studies do not provide an interpretable disease progression signature, nor do they allow for future extension to seamlessly…”
Method
Metadata
- Authors
- Schneider, L. S., Frangakis, C., Drye, L. T., Devanand, D. P., Marano, C. M., Mintzer, J., Mulsant, B. H., Munro, C. A., Newell, J. A., Pawluczyk, S., Pelton, G., Pollock, B. G., Porsteinsson, A. P., Rabins, P. V., Rein, L., Rosenberg, P. B., Shade, D., Weintraub, D., Yesavage, J., Lyketsos, C. G., & for the CitAD Research Group
- Venue
- American Journal of Psychiatry
- Published
- 2016-05-01
- Volume
- 173
- Issue
- 5
- Pages
- 465-472
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2236030964
- Cited by
- 95
- References
- 11
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.